### **BIOGRAPHICAL SKETCH**

POSITION TITLE

Allison W. Kurian, M.D., M.Sc.		Assistant Professor of Medicine and of Health Research and Policy		
EDUCATION/TRAINING				
INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY	
Stanford University B.	.A.	1995	Human Biology, Honors	
Harvard Medical School M	I.D.	1999	Medicine	
Massachusetts General Hospital Re	esidency	1999-2002	Internal Medicine	
Harvard School of Public Health		2000	Clinical Effectiveness Program	

2002-2005

2006

Medical Oncology

Epidemiology

Fellowship

M.Sc.

## **Professional Experience:**

Stanford University School of Medicine

Stanford University School of Medicine

NAME

1999-2002	Intern and Resident in Internal Medicine, Massachusetts General Hospital
2002-2005	Post-Doctoral Fellow, Division of Oncology, Stanford University
2006-2007	Instructor in Medicine, Division of Oncology, Stanford University
2007-	Associate Director, Stanford Program for Clinical Cancer Genetics
2007-	Member, Stanford University Cancer Institute, Cancer Epidemiology Program
2008-	Assistant Professor of Medicine and of Health Research and Policy, Stanford University
2013-	Member, Stanford University Cancer Institute, Cancer Prevention and Control Program

# **Professional Certification:**

2002 Certified, Internal Medicine, American Board of Internal Medicine 2005 Certified, Medical Oncology, American Board of Internal Medicine

### Other Professional Activities and Experience:

	and received und Dapertenees.
2004-	Manuscript Reviewer, Annals of Internal Medicine, Breast Cancer Research, Breast Cancer Research and
	Treatment, Cancer, Cancer Epidemiology Biomarkers and Prevention, Cancer Investigation, Cancer Prevention
	Research, Cancer Research, Carcinogenesis, Clinical Cancer Research, European Journal of Cancer, International
	Journal of Cancer, JAMA, Journal of Clinical Oncology, Nature Biotechnology, PLoS Genetics, Value in Health
2008	Data Relevance Working Group, Surveillance Epidemiology and End Results (SEER) Registry
2008-2011	Career Development Subcommittee, American Society of Clinical Oncology (ASCO)
2009-	Guidelines Panel on Genetic Risk of Breast and Ovarian Cancer, National Comprehensive Cancer Network
2011-	Board of Directors, American Cancer Society, Santa Clara County Chapter
2011-	Scientific Advisory Board, FORCE Patient Advocacy Organization for Hereditary Breast and Ovarian Cancer
2011-2012	Scientific Program Committee, Epidemiology Section, American Association for Cancer Research (AACR)
2011-2014	Scientific Program Committee, Cancer Prevention and Epidemiology, ASCO Annual Meeting
2012-2015	Scientific Program Committee, ASCO Quality Care Symposium
2012-	Advisory Committee, California Health Care Foundation
2013-	Faculty Advisor on Cancer Genetics, San Francisco Bay Area Biotechnology Education Consortium
2013-	Member, California Breast Density Information Group
2013-	Guidelines Panel on Breast Cancer Risk Reduction, National Comprehensive Cancer Network
2013-2014	Track Leader for Cancer Prevention and Epidemiology, Scientific Program Committee, ASCO Annual Meeting
2014-	Oncology Consultant, NCI-funded Cancer Intervention and Surveillance Modeling Network (CISNET)
2014-	Associate Member, Canary Center at Stanford for Cancer Early Detection
	· · · · · · · · · · · · · · · · · · ·

### **Awards and Honors:**

1995	Phi Beta Kappa, Stanford University
2003	Award for best research abstract, Division of Oncology, Stanford University
2004	American Society of Clinical Oncology Merit Award for Research Abstract
2005	American Society of Clinical Oncology Young Investigator Award
2005	Cancer Research and Prevention Foundation Post-Doctoral Fellowship Award
2005	California Breast Cancer Research Program Post-Doctoral Fellowship Award
2006	National Institutes of Health Building Interdisciplinary Research Careers in Women's Health K12 Award
2007	Cornelius L. Hopper Research Impact Award, California Breast Cancer Research Program Symposium
2008	Robert Wood Johnson Foundation Physician Faculty Scholars Award
2008	Jan Weimer Faculty Chair for Breast Oncology, Stanford University Cancer Institute
2010	California Breast Cancer Research Program Translational Research Award
2011	New Clinical Investigator Award, Stanford University Cancer Institute
2011	Top 12 publications of the National Cancer Institute (NCI)'s Epidemiology and Genomics Research Program
2013	Suzanne Pride Bryan Award for Breast Cancer Research, Stanford University Cancer Institute

#### **Peer-Reviewed Publications (53):**

- 1. Hartman AR, Daniel BL, **Kurian AW**, et al. Breast MRI screening and ductal lavage in women at high genetic risk of breast cancer. Cancer 2004; 100:479-89
- 2. **Kurian AW**, Balise RB, McGuire VM, Whittemore AS. Histologic subtypes of epithelial ovarian cancer: have they different risk factors? <u>Gynecol Oncol</u> 2005; 96:520-30
- 3. **Kurian AW**, Mills MA, Jaffee M, et al. Ductal lavage of fluid-yielding and non-fluid-yielding ducts in *BRCA1* and *BRCA2* mutation carriers and other women with high inherited risk. <u>Cancer Epidemiology Biomarkers and Prevention</u> 2005; 14:1082-9
- 4. **Kurian AW**, Hartman AR, Mills MA, et al. Opinions of women with high inherited breast cancer risk about prophylactic mastectomy. Health Expect 2005; 8:221-33
- 5. Kim SM, Hatami F, Harris JS, **Kurian AW**, et al. Bio-medical terahertz imaging with a quantum cascade laser. <u>Appl Phys Lett</u> 2006; 88:153903
- 6. Plevritis SK, **Kurian AW**, Sigal BM, et al. Cost-effectiveness of screening breast magnetic resonance imaging for women with *BRCA* mutations. JAMA 2006; 295:2374-84
- 7. **Kurian AW**, Newton Thompson R, Gaw AF, et al. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER-2/neu-positive breast cancer. J Clin Oncol 2007; 25:634-41; with an editorial
- 8. Ghanouni P, **Kurian AW**, Margolis D, et al. Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage. <u>Breast J</u> 2007; 13:281-6
- 9. Norton JD, Ham C, Van Dam J, Jeffrey RB, Longacre TA, Huntsman DJ, Chun NM, **Kurian AW**, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy. <u>Ann Surg</u> 2007; 245:873-9
- 10. Ghataorhe P, **Kurian AW**, Pickart A, et al. A carrier of both MEN1 and *BRCA2* mutations: a case report and review of the literature. <u>Cancer Genet Cytogenet</u> 2007; 179:89-92
- 11. Staton AD, **Kurian AW**, Cobb K, et al. Cancer risk reduction and reproductive concerns in female *BRCA1/2* mutation carriers. Fam Cancer 2007; 7:179-86
- 12. **Kurian AW**, Hartman AR, Mills MA, et al. Magnetic resonance galactography: feasibility in women with prior atypical breast duct cytology. <u>Breast J</u> 2008; 14:89-92
- 13. **Kurian AW**, Gong GD, Chun NM, et al. Performance of *BRCA1/2* mutation prediction models in Asian Americans. <u>J Clin Oncol</u> 2008; 26:4752-8
- 14. **Kurian AW**, Whittemore AS, Ford JM. In reply to "Tailoring BRCRAPRO to Asian Americans" by S. Chen et al. <u>J Clin Oncol</u> 2009; 27:643-4
- 15. Kurian AW, et al. The decline in breast cancer incidence: real or imaginary? Curr Oncol Rep 2009; 11:21-8
- 16. **Kurian AW**, Gong G, John E, et al. Performance of prediction models for *BRCA* mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry. <u>Cancer Epidemiol Biomarkers Prev</u> 2009; 18:1084-91
- 17. **Kurian AW,** McClure LA, John EM, et al. Second primary breast cancer occurrence according to hormone receptor status. <u>J Natl Cancer Inst</u> 2009; 101:1058-65
- 18. Vinayak S, **Kurian AW**. Statins may reduce the risk of breast cancer, particularly hormone receptor-negative disease. <u>Curr Breast Cancer Rep</u> 2009; 1:148-56
- 19. **Kurian AW**, Sigal BM, Plevritis SK. A survival analysis of cancer risk reduction strategies for *BRCA1/2* mutation carriers. <u>J Clin Oncol</u> 2010; 28:222-31; *with an editorial*
- 20. **Kurian AW**. *BRCA1* and *BRCA2* mutations across race and ethnicity: distribution and clinical implications. <u>Curr Opin Obstet Gynecol</u> 2010; 22:72-8
- 21. Gomez SL, Lichtensztajn D, **Kurian AW**, et al. Increasing mastectomy rates for early-stage breast cancer? Population-based trends from California. <u>J Clin Oncol</u> 2010; 28:e155-7
- 22. Kwong A, Ng EK, Law FB, Wong LP, To MY, Cheung MT, Wong HN, Chan VW, **Kurian A,** West DW, Ford JM, Ma ES. High-resolution melting analysis for rapid screening of *BRCA2* founder mutations in Southern Chinese breast cancer patients. <u>Breast</u> Cancer Res Treat 2010; 122:605-7.
- 23. Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlman W, **Kurian A**, et al. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2010; 8:562-94
- 24. Telli ML, Chang ET, **Kurian AW**, et al. Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat 2011; 127:471-8
- 25. **Kurian AW,** Fish K, Shema SJ, Clarke CA. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. <u>Breast Cancer Res</u> 2010; 12:R99; *highly accessed*
- 26. Chen Y, Kingham K, Ford JM, Rosing J, Van Dam J, Jeffrey RB, Longacre TA, Chun N, **Kurian A**, et al. A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer. Ann Surg Oncol 2011;18:2594-8.
- 27. Lebensohn A, Kingham K, Chun N, Kurian AW. Hereditary cancer: counseling women at risk. Contemp OB/GYN 2011; 56:30-8
- 28. **Kurian AW**, Gong GD, John EM, et al. Breast cancer risk for non-carriers of family-specific *BRCA1* and *BRCA2* mutations: findings from the Breast Cancer Family Registry. <u>J Clin Oncol</u> 2011; 29:4505-9, with an editorial and news release; selected as one of the 12 best publications funded by the NCI's Epidemiology and Genomics Research Program in 2011
- 29. **Kurian AW**, Whittemore AS. In reply to "Breast cancer risk for non-carriers of family specific *BRCA1* and *BRCA2* mutations: more trouble with phenocopies" by D. Evans et al. <u>J Clin Oncol</u> 2012; 30:1143-4
- 30. **Kurian AW**, Munoz DM, Rust P, et al. Online tool to guide decisions for *BRCA1/2* mutation carriers. <u>J Clin Oncol</u> 2012; 30:497-506, with an editorial and a news feature by the Robert Wood Johnson Foundation

- 31. Kwong A, Wong HN, Co M, **Kurian AW**, et al. The accuracy of *BRCA1/2* mutation prediction models in different ethnicities and genders: experience in a Southern Chinese cohort. World J Surg 2012; 36:702-13
- 32. Gomez SL, Press D, Lichtensztajn D, Keegan THM, Shema SJ, Le GM, **Kurian AW**. Patient, hospital, and neighborhood factors associated with treatment of early-stage breast cancer among Asian American women in California. <u>Cancer Epidemiol</u> Biomarkers Prev 2012; 21:821-34
- 33. Clarke CA, Keegan THM, Yang J, Press D, **Kurian AW**, et al. Age-specific incidence of breast cancer subtypes: understanding the "black-white crossover". J Natl Cancer Inst 2012; 104:1094-1101
- 34. Keegan THM, DeRouen MC, Press D, **Kurian AW**, Clarke CA. Occurrence of breast cancer subtypes in adolescent and young adult women. <u>Breast Cancer Res</u> 2012; 14:R55
- 35. Powell AA, Talasaz AA, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RA, Carlson RW, Mollick J, Sheth S, **Kurian AW**, et al. Single cell profiling of circulating tumor cells: transcriptional diversity between breast cancer cell lines and clinical samples. <u>PLoS One</u> 2012; 7(5): e33788
- 36. Sigal BM, Munoz DF, **Kurian AW**, Plevritis SK. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of *BRCA1/2* mutation carriers. <u>Cancer Epidemiol Biomarkers Prev</u> 2012; 21:1066-77
- 37. de Bruin MA, Kwong A, Goldstein BA, Lipson JA, Ikeda DM, McPherson L, Sharma B, Kardashian A, Schackmann EA, Kingham KE, Mills MA, West D, Ford JM, **Kurian AW**. Breast cancer risk factors differ between Asian and white women with *BRCA1/2* mutations. Fam Cancer 2012; 11:429-39
- 38. de Bruin M, Ford JM, **Kurian AW**. Genetic polymorphisms as predictors of breast cancer risk. <u>Curr Breast Cancer Rep</u> 2012; 4:232-9; DOI:10.1007/s12609-012-0091-7
- 39. Kwong A, Ng E, Wong CL, Law F, Au T, Wong H, **Kurian AW**, et al. Identification of *BRCA1/2* founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis. <u>PLoS One</u>. 2012; 7(9):e4399
- 40. Kwong A, Ng EK, Law FB, Wong HN, Wa A, Wong CL, **Kurian AW**, et al. Novel *BRCA1* and *BRCA2* genomic rearrangements in Southern Chinese breast/ovarian cancer patients. <u>Breast Cancer Res Treat</u> 2012; 136:931-3
- 41. Weber SC, Seto T, Olson C, Kenkare P, Kurian AW, Das AK. Oncoshare: Lessons learned from building an integrated multi-institutional database for comparative effectiveness research. AMIA Annu Symp Proc 2012:970-8
- 42. **Kurian AW**, Lichtensztajn D, Keegan THM, et al. Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007. Breast Cancer Res Treat 2013; 137:247-60
- 43. Schackmann EA, Munoz DF, Mills MA, Plevritis SK, **Kurian AW**. Feasibility evaluation of an online tool to guide decisions for *BRCA1/2* mutation carriers. Fam Cancer 2013; 12:65-73
- 44. de Bruin MA, Ford JM, **Kurian AW**. A young woman with bilateral breast cancer: Identifying a genetic cause and implications for management. J Natl Compr Canc Netw 2013; 11:512-7
- 45. **Kurian AW**, Edge SB. Information technology interventions to improve cancer care quality: A report from the American Society of Clinical Oncology Quality Care Symposium. J Oncol Pract 2013; 9:142-4
- 46. Wu AH, Gomez SL, Vigen C, Kwan ML, Keegan THM, Lu Y, Shariff-Marco S, Monroe KR, **Kurian AW**, et al. The California Breast Cancer Survivorship Consortium (CBCSC): Prognostic factors associated with racial/ethnic differences in breast cancer survival. <a href="Cancer Causes Control"><u>Cancer Causes Control</u></a> 2013; 24:1821-36
- 47. Price ER, Hargreaves J, Lipson JA, Sickles EA, Brenner RJ, Lindfors KK, Joe BN, Leung JWT, Feig SA, Bassett LW, Ojeda-Fournier H, Daniel B, **Kurian AW**, et al. The California Breast Density Information Group: a collaborative response to the issues of breast density, cancer risk, and notification legislation. <u>Radiology</u> 2013; 269:887-92
- 48. DeRouen MC, Gomez SL, Press DJ, Tao L, **Kurian AW**, Keegan THM. A population-based observational study of first-course treatment and survival for adolescent and young adult females with breast cancer. <u>J Adolesc Young Adult Oncol</u> 2013; 2:95-103
- 49. Keegan THM, Press DJ, Tao L, DeRouen MC, **Kurian AW**, Clarke CA, Gomez SL. Impact of breast cancer subtypes on three-year survival among adolescent and young adult women. Breast Cancer Research 2013; 15:R95
- 50. Vinayak S, Schwartz EJ, Jensen K, Lipson J, Alli E, McPherson L, Fernandez A, Sharma VB, Staton A, Mills MA, Schackmann EA, Telli ML, Kardashian A, Ford JM, **Kurian AW**. A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. <u>Breast Cancer Res Treat</u> 2013; 142:389-98
- 51. Kwan M, John E, Lee V, Bernstein L, Cheng I, Gomez S, Keegan T, **Kurian AW**, et al. Obesity and survival after breast cancer by race: the California Breast Cancer Survivorship Consortium. <u>Am J Epidemiol</u> 2014; 179:95-111
- 52. **Kurian AW**, Mitani MS, Desai M, et al. Breast cancer treatment across healthcare systems: linking electronic medical records and state registry data to enable outcomes research. Cancer 2014; 120:103-11
- 53. **Kurian AW**, Hare EE, Mills MA, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. <u>J Clin Oncol</u>; in press, *with an editorial*

#### **Selected Presentations at National and International Meetings (from a total of 61):**

- 1. **Kurian AW**. "A Global Perspective on *BRCA1/2* Mutations". Oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, Special Session on Global Perspective on in Female Malignancies, Orlando, FL, May 2009
- 2. **Kurian AW**, Plevritis, SK. "A Decision Tool for Women with *BRCA1/2* Mutations". Oral presentation at the Australia-New Zealand Breast Cancer Clinical Trials Group Annual Meeting, Hobart, Tasmania, July 2012
- 3. Kurian AW. "Genomics of Breast Cancer Susceptibility". Oral presentation at the ASCO Annual Meeting, Chicago, IL, June 2013
- 4. **Kurian AW**. "Genomics of Hereditary Breast Cancer: Strategies and Guidelines". Oral presentation at the San Antonio Breast Cancer Symposium, Satellite Symposium on *BRCA* Mutations; San Antonio, TX, December 2013

<b>Awarded Resea</b> 2012-2014	Funder: Stanford Cancer Institute, Developmental Research Award in Population Science Title: Emerging Diagnostic Technology in Breast Cancer Care: A Comparative Effectiveness Study; Role: P.I.
2013-2014	Funder: Breast Cancer Research Foundation Title: The Oncoshare Project: An Informatics Approach to Therapeutic Discovery in Breast Cancer Role: Co-P.I. (Co-P.I.: George W. Sledge Jr., Stanford University)
<u>Past Support:</u> 2005-2006	Funder: California Breast Cancer Research Program, Post-Doctoral Fellowship Title: Cost-Effectiveness of Screening MRI by Cancer Risk; Role: Post-Doctoral Fellow
2005-2006	Funder: American Society of Clinical Oncology, Young Investigator Award Title: Lovastatin for Modification of Breast Cancer-Associated Biomarkers; Role: Post-Doctoral Fellow
2005-2007	Funder: Cancer Research and Prevention Foundation, Post-Doctoral Fellowship Title: Lovastatin for Modification of Breast Cancer-Associated Biomarkers; Role: Post-Doctoral Fellow
2005-2008	Funder: Susan G. Komen Breast Cancer Foundation, Population-Specific Research Award Title: A Clinic-Based Study of <i>BRCA</i> Mutations in Asians and Caucasians Role: Co-I. (P.I.: James M. Ford)
2006-2008	Funder: National Institutes of Health, BIRCWH K12 Award Title: Ethnic Differences in Hereditary Breast and Ovarian Cancer; Role: Research Scholar
2007-2008	Funder: Stanford Cancer Institute, Developmental Research Award in Population Science Title: A Tool to Guide Risk-Reduction Decisions in <i>BRCA</i> Carriers; Role: Co-I. (P.I.: Sylvia K. Plevritis)
2007-2009	Funder: National Institutes of Health, R03 CA130065-01 Title: Study of Genetic Mutations in Chinese Populations with Breast Cancer; Role: Co-I. (P.I.: Dee West, CPIC)
2008-2010	Funder: Stanford Cancer Institute (Developmental Research Award in Population Science) Title: <i>BRCA1/2</i> Carriers in Asia vs. the U.S.: What Determines Differences in Breast Cancer Risk?; Role: P.I.
2008-2010	Funder: National Cancer Institute, N01-PC-35136 Title: Improving Understanding of Breast Cancer Health Disparities Using Linked Data Sets Role: Co-I. (P.I.: Scarlett L. Gomez, Cancer Prevention Institute of California (CPIC))
2008-2011	Funder: Robert Wood Johnson Foundation, Physician Faculty Scholars Program Award 64317 Title: Breast Cancer Risk Reduction Strategies: Optimizing Their Use by Physicians and Patients; Role: P.I.
2008-2013	Funder: National Institutes of Health, R01 EB009055-01 Title: High-Resolution Whole-Breast MRI at 3.0T Role: Co-Investigator (Co-I.); Principal Investigator (P.I.): Brian Hargreaves, Stanford University
2010-2013	Funder: California Breast Cancer Research Program, Translational Research Award 16OB-0149 Title: Measuring Real-World Breast Cancer Care; Role: P.I.
2011-2012	Funder: Stanford Cancer Institute, Developmental Research Award in Population Science Title: Can Emerging Tests Improve Cancer Risk Assessment?; Role: P.I.
2011-2013	Funder: California Breast Cancer Research Program, Special Projects Award Title: California Breast Cancer Survivorship Consortium; Role: Co-I. (P.I.: Anna Wu, Univ. of Southern California)
2012-2013	Funder: Stanford Cancer Institute, Developmental Research Award in Population Science Title: Melatonin and Breast Cancer Risk. Role: Co-I. (P.I.: Ann Hsing, CPIC)
2012-2013	Funder: Stanford Hospital and Clinics Innovation Fund Award Title: Colorectal Cancer Screening Tailored to Risk; Role: Co-I. (P.I.: Uri Ladabaum, Stanford University)
2012-2014	Funder: Stanford Cancer Institute, Developmental Research Award in Population Science Title: Influence of Social Networking on Breast Cancer Survivors. Role: Co-I. (P.I.: Gem Le, CPIC)